Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7
Marianthi Papanagiotou, Zoe H Dailiana, Theophilos Karachalios, Sokratis Varitimidis, Michael Hantes, Konstantinos N Malizos, Department of Orthopaedic Surgery, Faculty of Medicine, University of Thessalia, 41500 Larissa, Greece
Georgios Dimakopoulos, Medical Statistics, Epirus Science and Technology Park, University of Ioannina Campus, 45500 Ioannina, Greece
Marianna Vlychou, Department of Radiology and Medical Imaging, Faculty of Medicine, University of Thessalia, 41500 Larissa, Greece
Author contributions: All the authors contributed to the manuscript.
Supported by The European Union (European Social Fund - ESF) and Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF)-Research Funding Program: Heracleitus II.
Institutional review board statement: This study was reviewed and approved by the Educational Board of the University Hospital of Larissa, Greece.
Informed consent statement: Patients provided informed consent to receive the specific treatment. In the present study the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data on this topic are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Zoe H Dailiana, MD, PhD, Associate Professor, Department of Orthopaedic Surgery, Faculty of Medicine, University of Thessalia, 3 Panepistimiou St, Biopolis, 41500 Larissa, Greece. dailiana@med.uth.gr
Telephone: +30-24-13502722 Fax: +30-24-13501011
Received: June 13, 2016
Peer-review started: June 20, 2016
First decision: July 29, 2016
Revised: August 29, 2016
Accepted: October 25, 2016
Article in press: October 27, 2016
Published online: January 18, 2017
Processing time: 211 Days and 19.6 Hours
Peer-review started: June 20, 2016
First decision: July 29, 2016
Revised: August 29, 2016
Accepted: October 25, 2016
Article in press: October 27, 2016
Published online: January 18, 2017
Processing time: 211 Days and 19.6 Hours
Core Tip
Core tip: Bone morphogenetic proteins are identified as factors promoting osteogenesis. In this study an attempt was made to estimate the rate of heterotopic bone formation in patients with long bone nonunions treated with recombinant human bone morphogenetic protein-7 (rhBMP-7), and to identify predisposing factors, related to the patient, the nonunion characteristics, and the surgical procedure. Eighteen percent of the patients developed heterotopic ossification on the radiographs, without functional limitations. All patients that developed heterotopic ossification were male. This rate of heterotopic ossification after rhBMP-7 use for the treatment of long bone nonunions is higher than the rates reported in literature.